Arvinas (ARVN) Revenue & Revenue Breakdown
Arvinas Revenue Highlights
Latest Revenue (Y)
$263.40M
Latest Revenue (Q)
$102.40M
Arvinas Revenue by Period
Arvinas Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $263.40M | 235.54% |
| 2023-12-31 | $78.50M | -40.26% |
| 2022-12-31 | $131.40M | 181.37% |
| 2021-12-31 | $46.70M | 114.20% |
| 2020-12-31 | $21.80M | -49.27% |
| 2019-12-31 | $42.98M | 200.03% |
| 2018-12-31 | $14.32M | 89.00% |
| 2017-12-31 | $7.58M | 13.64% |
| 2016-12-31 | $6.67M | - |
Arvinas generated $263.40M in revenue during NA 2024, up 235.54% compared to the previous quarter, and up 612.89% compared to the same period a year ago.
Arvinas Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $102.40M | 33.86% |
| 2024-06-30 | $76.50M | 202.37% |
| 2024-03-31 | $25.30M | -158.70% |
| 2023-12-31 | $-43.10M | -224.57% |
| 2023-09-30 | $34.60M | -36.51% |
| 2023-06-30 | $54.50M | 67.69% |
| 2023-03-31 | $32.50M | -14.47% |
| 2022-12-31 | $38.00M | 25.41% |
| 2022-09-30 | $30.30M | -3.19% |
| 2022-06-30 | $31.30M | 29.34% |
| 2022-03-31 | $24.20M | -7.98% |
| 2021-12-31 | $26.30M | 183.26% |
| 2021-09-30 | $9.28M | 67.46% |
| 2021-06-30 | $5.54M | 0.09% |
| 2021-03-31 | $5.54M | 149.78% |
| 2020-12-31 | $2.22M | -70.81% |
| 2020-09-30 | $7.60M | 32.17% |
| 2020-06-30 | $5.75M | -7.88% |
| 2020-03-31 | $6.24M | 27.51% |
| 2019-12-31 | $4.89M | -83.72% |
| 2019-09-30 | $30.05M | 648.17% |
| 2019-06-30 | $4.02M | - |
| 2019-03-31 | $4.02M | 16.75% |
| 2018-12-31 | $3.44M | 1.92% |
| 2018-09-30 | $3.38M | -0.72% |
| 2018-06-30 | $3.40M | -17.25% |
| 2018-03-31 | $4.11M | 59.73% |
| 2017-12-31 | $2.57M | 54.13% |
| 2017-09-30 | $1.67M | - |
| 2017-06-30 | $1.67M | - |
| 2017-03-31 | $1.67M | - |
Arvinas generated $102.40M in revenue during Q3 2024, up 33.86% compared to the previous quarter, and up 187.89% compared to the same period a year ago.
Arvinas Revenue Breakdown
Arvinas Revenue Breakdown by Product
Quarterly Revenue by Product
| Product/Service | Sep 24 | Jun 24 |
|---|---|---|
| License | $130.00M | $130.00M |
Latest
Arvinas's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: License (100.00%).
Arvinas Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| RARE | Ultragenyx Pharmaceutical | $560.23M | $147.03M |
| ARVN | Arvinas | $263.40M | $102.40M |
| NRIX | Nurix Therapeutics | $54.55M | $12.59M |
| KURA | Kura Oncology | $53.88M | - |
| KYMR | Kymera Therapeutics | $47.07M | $3.74M |
| FHTX | Foghorn Therapeutics | $34.16M | $7.81M |
| CCCC | C4 Therapeutics | $20.76M | - |
| RLAY | Relay Therapeutics | $10.01M | - |
| STOK | Stoke Therapeutics | $8.78M | $4.89M |
| IPSC | Century Therapeutics | $2.23M | $791.00K |
| STTK | Shattuck Labs | $1.66M | $1.61M |
| PLRX | Pliant Therapeutics | $1.58M | - |
| CRNX | Crinetics Pharmaceuticals | $1.04M | - |
| BDTX | Black Diamond Therapeutics | - | - |
| RVMD | Revolution Medicines | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |